Small Molecules

10 Oct 2017 Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
10 Oct 2017 Data Monitoring Committee Unanimously Recommends Continuation of Combioxin First-in-Human Clinical Trial with CAL02 in Patients with Severe Pneumococcal Pneumonia
10 Oct 2017 Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials
10 Oct 2017 Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek™ 2017
10 Oct 2017 Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
10 Oct 2017 GNI Group Announces Clearance of Investigational New Drug (IND) by FDA for F351 Clinical Trials in the Treatment of Liver Fibrosis
10 Oct 2017 OncoArendi Therapeutics to Begin the Phase 1 Clinical Evaluation of its Novel Class of Medicines
10 Oct 2017 Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017
09 Oct 2017 EDO announces next milestone for tinostamustine (EDO-S101) as first-in-human solid tumor study begins
09 Oct 2017 Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
07 Oct 2017 Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain
06 Oct 2017 Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
06 Oct 2017 SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis
06 Oct 2017 NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
05 Oct 2017 Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens
04 Oct 2017 Melior Pharmaceuticals Initiates Phase 2b Study with MLR-1023 for Type 2 Diabetes
04 Oct 2017 Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018
04 Oct 2017 Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Meniere's Disease
04 Oct 2017 ImmunoMet Announces Initiation of Phase 1 Clinical Study of IM156, an OXPHOS Inhibitor, in Patients with Solid Tumors
04 Oct 2017 RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial in Patients with Type 2/3 Spinal Muscular Atrophy
04 Oct 2017 Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform
04 Oct 2017 Motif Bio Announces Positive Topline Results for iclaprim in the REVIVE-2 Phase 3 Study
03 Oct 2017 Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study
03 Oct 2017 Vantia Therapeutics Announces Positive Results From its Phase III EQUINOC Study, a Pivotal Trial with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia
03 Oct 2017 Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing